George Poste

Q: What Schools Are Affiliated With George Poste

George Poste is affiliated with the following schools: University of California, Irvine, University of Leeds, University of Bristol, University of Manchester, Thomas Jefferson University, Arizona State University, University of Pennsylvania

George Poste's AcademicInfluence.com Rankings

George Poste

Biology

#2851

World Rank

#4458

Historical Rank

#1228

USA Rank

Systems Biology

World Rank

Historical Rank

USA Rank

Biotechnology

#26

World Rank

#26

Historical Rank

#11

USA Rank

Computational Biology

#69

World Rank

#69

Historical Rank

#22

USA Rank

biology Degrees

Download Badge

Biology

Why Is George Poste Influential?

(Suggest an Edit or Addition)

According to Wikipedia, George Henry Poste, CBE FRS, is a former Director of the Biodesign Institute at Arizona State University. Career Poste is the Del E. Webb Professor of Health Innovation and Chief Scientist at The Complex Adaptive Systems Initiative at Arizona State University . This program integrates research in genomics, synthetic biology and high performance computing to study the altered regulation of molecular networks in human diseases to develop new diagnostic tests for precision medicine and the remote monitoring of health status using miniaturized body sensors and mobile devices. He assumed this post in 2009. From 2003 to 2009 he directed and built The Biodesign Institute at ASU.

(See a Problem?)

George Poste's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The pathogenesis of cancer metastasis (1980) (1733)
Bring on the biomarkers (2011) (518)
Cochleate lipid cylinders: formation by fusion of unilamellar lipid vesicles. (1975) (476)
The "seed and soil" hypothesis revisited. (2008) (449)
In vitro selection of murine B16 melanoma variants with enhanced tissue-invasive properties. (1980) (432)
Membrane fusion and molecular segregation in phospholipid vesicles. (1974) (415)
Studies on membrane fusion. III. The role of calcium-induced phase changes. (1977) (410)
Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. (1982) (318)
Interactions among clonal subpopulations affect stability of the metastatic phenotype in polyclonal populations of B16 melanoma cells. (1981) (317)
Effects of local anesthetics on membrane properties. I. Changes in the fluidity of phospholipid bilayers. (1975) (313)
Studies on membrane fusion. II. Induction of fusion in pure phospholipid membranes by calcium ions and other divalent metals. (1976) (297)
Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol. (1998) (250)
Arrest and metastasis of blood-borne tumor cells are modified by fusion of plasma membrane vesicles from highly metastatic cells. (1980) (246)
Liposome targeting in vivo: Problems and opportunities (1983) (228)
Fusion of mammalian cells by unilamellar lipid vesicles: inflluence of lipid surface charge, fluidity and cholesterol. (1973) (226)
Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators. (1982) (214)
Biological characterization and oncogene expression in human colorectal carcinoma cell lines (1988) (195)
The search for antimicrobial agents effective against bacteria resistant to multiple antibiotics (1997) (194)
Design of liposomes to improve delivery of macrophage-augmenting agents to alveolar macrophages. (1980) (191)
Measurement of the lateral mobility of cell surface components in single, living cells by fluorescence recovery after photobleaching. (1976) (188)
Effects of local anesthetics on cell morphology and membrane-associated cytoskeletal organization in BALB/3T3 cells (1976) (185)
Lipid vesicles as carriers for introducing materials into cultured cells: influence of vesicle lipid composition on mechanism(s) of vesicle incorporation into cells. (1976) (180)
Local anesthetics affect transmembrane cytoskeletal control of mobility and distribution of cell surface receptors. (1975) (174)
Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. (1993) (171)
Measurement of the translational mobility of concanavalin A in glycerol-saline solutions and on the cell surface by fluorescence recovery after photobleaching. (1976) (171)
The cell surface in animal embryogenesis and development (1979) (169)
The cancer cell: dynamic aspects and modifications in cell-surface organization (first of two parts). (1976) (168)
Studies on membrane fusion. I. Interactions of pure phospholipid membranes and the effect of myristic acid, lysolecithin, proteins and dimethylsulfoxide. (1976) (166)
Mechanisms of virus-induced cell fusion. (1972) (166)
Site–Specific (Targeted) Drug Delivery in Cancer Therapy (1983) (157)
Evolution of tumor cell heterogeneity during progressive growth of individual lung metastases. (1982) (151)
Incorporation of lipid vesicles by mammalian cells provides a potential method for modifying cell behaviour (1974) (148)
The Cell surface and neuronal function (1980) (148)
Tumorigenic and metastatic properties of "normal" and ras-transfected NIH/3T3 cells. (1985) (144)
Activation of tumoricidal properties in mouse macrophages by lymphokines encapsulated in liposomes. (1979) (143)
Flow Cytometry: Present and Future (1985) (139)
Biochemical, morphological, and ultrastructural studies on the uptake of liposomes by murine macrophages. (1981) (138)
Cellular uptake of cyclic AMP captured within phospholipid vesicles and effect on cell-growth behaviour. (1974) (135)
On the genesis and regulation of cellular heterogeneity in malignant tumors. (1982) (132)
Lipid vesicles as carriers for introducing biologically active materials into cells. (1976) (129)
Effects of local anesthetics on membrane properties. II. Enhancement of the susceptibility of mammalian cells to agglutination by plant lectins. (1975) (126)
The cellular heterogeneity of malignant neoplasms: implications for adjuvant chemotherapy. (1985) (122)
Induction of 32- and 34-kDa stress proteins by sodium arsenite, heavy metals, and thiol-reactive agents. (1986) (119)
Comparison of the metastatic properties of B16 melanoma clones isolated from cultured cell lines, subcutaneous tumors, and individual lung metastases. (1982) (118)
Tumor implantation and invasion at metastatic sites. (1983) (113)
Studies on Membrane Fusion with Natural and Model Membranes (1979) (113)
Virus-induced polykaryocytosis and the mechanism of cell fusion. (1970) (111)
An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. (1988) (109)
Tumor cell diversity and host responses in cancer metastasis--part I--properties of metastatic cells. (1982) (109)
Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE (2017) (109)
Tissue dissociation with proteolytic enzymes. Adsorption and activity of enzymes at the cell surface. (1971) (103)
Dynamic aspects of cell surface organization (1977) (102)
New Generation Vaccines (1993) (100)
Membrane fusion reaction: a theory. (1971) (100)
Parkinson's disease: prospects for improved drug therapy. (1997) (99)
Sharing Publication-Related Data and Materials: Responsibilities of Authorship in the Life Sciences1 (2003) (98)
Inhibition of T suppressor cell expression by histamine type 2 (H2) receptor antagonists. (1984) (92)
Rapid decay of tumoricidal activity and loss of responsiveness to lymphokines in inflammatory macrophages. (1979) (91)
Use of lipid vesicles as carriers to introduce actinomycin D into resistant tumor cells. (1976) (87)
The Synthesis, assembly and turnover of cell surface components (1977) (85)
Cell surface receptors for lymphokines. I. The possible role of glycolipids as receptors for macrophage migration inhibitory factor (MIF) and macrophage activation factor (MAF). (1979) (84)
Inhibition of macrophage activation by calcium channel blockers and calmodulin antagonists. (1985) (83)
SK&F 86002: a structurally novel anti-inflammatory agent that inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid. (1987) (80)
Immunological Adjuvants and Vaccines (1989) (78)
Rat alveolar macrophages are susceptible to activation by free and liposome-encapsulated lymphokines. (1980) (77)
Carvedilol: A Novel Cardiovascular Drug with Multiple Actions (1992) (72)
Pathogenesis of metastatic disease: implications for current therapy and for the development of new therapeutic strategies. (1986) (66)
Tumor cell diversity and host responses in cancer metastasis--part II--host immune responses and therapy of metastases. (1983) (66)
Studies on the cytopathogenicity of Newcastle disease virus: relation between virulence, polykaryocytosis and plaque size. (1971) (66)
Tumor heterogeneity and progression: conceptual foundations for modeling. (1996) (65)
Isolation of a herpesvirus from the canine genital tract: association with infertility, abortion and stillbirths (1971) (64)
Growth of mammalian cells on substrates coated with cellular microexudates. I. Effect on cell growth at low population densities (1975) (64)
Colon cancer cells (1990) (63)
Cytoskeletal elements and plasma membrane organization (1981) (62)
New approaches to the control of infections caused by antibiotic-resistant bacteria. An industry perspective. (1996) (62)
Receptor-Mediated Targeting of Drugs (1984) (61)
Development of GPIIb/IIIa antagonists as antithrombotic drugs. (1992) (59)
Experimental metastasis correlates with cyclic AMP accumulation in B16 melanoma clones (1984) (58)
Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease (1982) (57)
The study of cellular "microexudates" by ellipsometry and their relationship to the cell coat. (1973) (57)
Statement on Scientific Publication and Security (2003) (55)
Sub-lethal autolysis. Modification of cell periphery by lysosomal enzymes. (1971) (55)
Calcium-induced phase separation and fusion in phospholipid membranes. (1975) (53)
Local anaesthetics increase susceptibility of untransformed cells to agglutination by concanavalin A (1975) (53)
Experimental systems for analysis of the malignant phenotype (2004) (52)
Inhibition of cell fusion by local anaesthetics and tranquillizers. (1972) (52)
Enucleation of mammalian cells by cytochalasin B. I. Characterization of anucleate cells. (1972) (49)
Drug-containing lipid vesicles render drug-resistant tumour cells sensitive to actinomycin D (1976) (49)
THE INFLUENCE OF VESICLE MEMBRANE PROPERTIES ON THE INTERACTION OF LIPID VESICLES WITH CULTURED CELLS (1978) (48)
Calcium ionophores A23187 and X537A affect cell agglutination by lectins and capping of lymphocyte surface immunoglobulins. (1976) (46)
Beyond Ebola: lessons to mitigate future pandemics (2015) (46)
Nullomers: Really a Matter of Natural Selection? (2007) (46)
In vitro tumoricidal activity of macrophages against virus-transformed lines with temperature-dependent transformed phenotypic characteristics. (1978) (45)
Changes in susceptibility of normal cells to agglutination by plant lectins following modification of cell coat material. (1972) (45)
The role of plasma membrane receptors and the kinetics of macrophage activation by lymphokines encapsulated in liposomes. (1981) (43)
Cell surface receptors for lymphokines. II. Studies on the carbohydrate composition of the MIF receptor on macrophages using synthetic saccharides and plant lectins. (1979) (42)
Inhibition of virus-induced cell fusion by local anaesthetics and phenothiazine tranquilizers. (1972) (42)
Leveling the Playing Field: Bringing Development of Biomarkers and Molecular Diagnostics up to the Standards for Drug Development (2012) (42)
1 – The dynamics of cell membrane organization (1977) (41)
Enucleation of mammalian cells by cytochalasin B. II. Formation of hybrid cells and heterokaryons by fusion of anucleate and nucleated cells. (1972) (41)
Statement on the consideration of biodefence and biosecurity (2003) (41)
Studies on the cytopathic effects of Newcastle disease virus: metabolic requirements. (1971) (40)
Improved flow cytometric analysis of leukocyte subsets: simultaneous identification of five cell subsets using two-color immunofluorescence. (1986) (40)
Macrophage content of spontaneous metastases at different stages of growth. (1987) (40)
Biospecimens, biomarkers, and burgeoning data: the imperative for more rigorous research standards. (2012) (40)
Increased Mobility and Redistribution of Concanavalin A Receptors on Cells infected with Newcastle Disease Virus (1974) (40)
5 – Liposomes as a Drug Delivery System in Cancer Therapy (1984) (39)
Streptomyces: a host for heterologous gene expression. (1991) (38)
Mechanisms of Receptor Regulation (1985) (37)
Converging and emerging threats to health security (2017) (37)
Changes in the macrophage content of lung metastases at different stages in tumor growth. (1985) (36)
Agglutination of normal cells by plant lectins following infection with nononcogenic viruses. (1972) (36)
Identification and characterization of a monoclonal antibody to an antigen expressed on activated macrophages. (1984) (36)
Molecular diagnostics: a powerful new component of the healthcare value chain (2001) (35)
Carvedilol update III: Rationale for use in congestive heart failure (1995) (35)
The tumoricidal properties of inflammatory tissue macrophages and multinucleate giant cells. (1979) (35)
Plasma Exosome Profiling of Cancer Patients by a Next Generation Systems Biology Approach (2017) (34)
Inflammatory Cells and Mediators in CNS Disease (2003) (34)
Effect of 5-azacytidine on DNA methylation and the malignant properties of B16 melanoma cells. (1985) (33)
Protein Design and the Development of New Therapeutics and Vaccines (1990) (32)
Drug Targeting in Cancer Therapy (1984) (31)
Prioritization schema for immunotherapy clinical trials in glioblastoma (2016) (31)
The national biomarker development alliance: confronting the poor productivity of biomarker research and development (2015) (31)
Modification of Newcastle disease virus release and cytopathogenicity in cells treated with plant lectins. (1974) (30)
Cellular binding of 3H‐cytochalasin B (1974) (29)
Anucleate mammalian cells: applications in cell biology and virology. (1973) (29)
Core Competencies in One Health Education: What Are We Missing? (2018) (29)
Uncensored exchange of scientific results (2003) (29)
The impact of genetics on medical education and training. (1999) (28)
Cells transformed by temperature-sensitive mutants of avian sarcoma virus cause tumors in vivo at permissive and nonpermissive temperatures (1979) (28)
Interactions between tumor cell subpopulations in malignant tumors. (1983) (28)
The growth and cytopathogenicity of virulent and attenuated strains of canine distemper virus in dog and ferret macrophages. (1971) (27)
Studies on the cytopathic effects of Newcastle disease virus: the cytopathogenicity of strain Herts 33 in five cell types. (1973) (27)
Synthesis of cell coat in normal and transformed cells. (1972) (27)
New Insights into Cell and Membrane Transport Processes (1986) (26)
Formation of hybrid cells and heterokaryons by fusion of enucleated and nucleated cells. (1971) (26)
Molecular Genetic Strategies for the Development of Anti-Malarial Vaccines (1985) (25)
New histochemical method for measuring intratumoral macrophages and macrophage recruitment into experimental metastases. (1983) (25)
Herpesvirus hominis infection of the female genital tract. (1972) (25)
Identification and characterization of a human T cell line-derived lymphokine with MAF-like activity distinct from interferon-gamma. (1986) (24)
Synthesis and evaluation of multisubstrate inhibitors of an oncogene-encoded tyrosine-specific protein kinase. 2. (1988) (24)
The study of surface reactions in biological systems by ellipsometry (1972) (24)
Production of a serine-protease with macrophage migration-inhibitory factor activity by virus-transformed cells and human tumor cell lines. (1975) (24)
Building Population Genetics Resources Using the U.K. NHS (1999) (23)
The pathogenesis of cancer metastasis. (review). (1980) (23)
Modulation of macrophage-lymphocyte interactions by the antiarthritic gold compound, auranofin. (1985) (22)
Drug Delivery to Macrophages for the Therapy of Cancer and Infectious Diseases (1987) (22)
Cell fusion by Newcastle disease virus. (1972) (22)
Mechanism of resistance to ricin toxin in selected mouse lymphoma cell lines. (1978) (22)
Methods and models for studying tumor invasion (1982) (21)
CELLULAR HETEROGENEITY IN MALIGNANT NEOPLASMS AND THE THERAPY OF METASTASES (1982) (20)
The biologic diversity of cancer metastases. (1982) (20)
Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes (2018) (20)
Liposome-mediated transfer of integral membrane glycoproteins into the plasma membrane of cultured cells. (1980) (20)
The case for genomic patenting. (1995) (19)
Membrane fusion. (1973) (19)
Reversal of multidrug resistance in murine fibrosarcoma cells by thioxanthene flupentixol (1994) (19)
The experimental and clinical implications of cellular heterogeneity in malignant tumors (2004) (18)
Targeting of Drugs With Synthetic Systems (1985) (17)
Macrophages and cancer metastasis. (1982) (17)
Isolation and analysis of an Abelson murine leukemia virus-encoded tyrosine-specific kinase produced in Escherichia coli. (1985) (17)
Interaction of Sendai virus with human erythrocytes: a system for the study of membrane fusion. (1972) (17)
Effects of tertiary amine local anesthetics on the blood-borne implantation and cell surface properties of metastatic mouse melanoma cells. (1986) (17)
Molecular medicine and information–based targeted healthcare (1998) (17)
Studies on the cytopathic effects of Newcastle disease virus: cell surface changes. (1972) (17)
Induction of mammalian stress proteins by a triethylphosphine gold compound used in the therapy of rheumatoid arthritis. (1986) (17)
Identification of a potential artifact in the use of electron microscope autoradiography to localize saturated phospholipids in cells. (1978) (17)
Cellular adhesion : molecular definition to therapeutic potential (1994) (16)
Heterogeneity of protein phosphorylation in metastatic variants of B16 melanoma. (1983) (16)
The synthesis of surface coat materials in normal and transformed cells. (1973) (16)
Studies on the cytopathic effects of Newcastle disease virus: RNA synthesis in infected cells. (1973) (16)
The interaction of phospholipid vesicles with mammalian cells in vitro. (1975) (15)
Fusion of mammalian cells by lipid vesicles. (1976) (15)
Virus-induced cell fusion enhanced by phytohaemagglutinin (1974) (15)
Inhibition of phytohaemagglutinin-induced proliferation of human peripheral blood lymphocytes by histamine and histamine H1 and H2 agonists. (1983) (15)
The National Biomarker Development Alliance accelerating the translation of biomarkers to the clinic. (2014) (15)
From vasopressin antagonist to agonist: A saga of surprise! (1991) (15)
Experimental systems for analysis of the surface properties of metastatic tumor cells. (1983) (14)
Toxicity studies of liposome-encapsulated immunomodulators administered intravenously to dogs and mice (2004) (14)
Production of macrophage migration inhbitory factor(s) (MIF) by virus-transformed cells. (1975) (14)
Stephen Paget, M.D., F.R.C.S., (1855–1926) A retrospective (1989) (14)
Rational or rationed medicine? The promise of genetics for improved clinical practice (2000) (13)
Cellular Adhesion (1994) (13)
Differential expression of murine macrophage-mediated tumor cytotoxicity induced by interferons. (1987) (12)
Production of C3 as a marker of lymphokine-mediated macrophage activation. (1984) (12)
Rescue of simian virus 40 (SV 40) from SV40-transformed cells by fusion with anucleate monkey cells and variation in the yield of virus rescued by fusion with replicating or nonreplicating monkey cells. (1974) (12)
Differential sensitivity of T suppressor cell expression to inhibition by histamine type 2 receptor antagonists. (1986) (12)
Studies on the cytopathogenicity of Newcastle disease virus: effect of lectins on virus infected cells. (1972) (12)
Induction by immunomodulatory agents of a macrophage antigen recognized by monoclonal antibody 158.2 and correlation with macrophage function. (1985) (12)
Liposome targeting to macrophages: opportunities for treatment of infectious diseases. (1986) (12)
Circumvention of multidrug-resistance in murine fibrosarcoma and colon-carcinoma cells by treatment with the alpha-adrenoceptor antagonist furobenzazepine. (1994) (12)
Reversal of histamine-mediated immunosuppression by structurally diverse histamine type II (H2) receptor antagonists. (1984) (11)
Targeting of drugs 4 : advances in system constructs (1994) (11)
Big Data and Health (2015) (11)
Some electrical properties of the peripheries of murine 3T3 cells with respect to viral transformation and reversion (1975) (11)
Induction of the 32-kD human stress protein by auranofin and related triethylphosphine gold analogs. (1988) (11)
Chemical derivatization of therapeutic proteins. (1993) (11)
Incorporating appropriate technology into North American schools of public health. (2006) (11)
Pharmacologic characterization of the antiinflammatory properties of a new dual inhibitor of lipoxygenase and cyclooxygenase (1987) (11)
The cancer cell: dynamic aspects and modification in cell-surface organization (second of two parts). (1976) (11)
The effect of cimetidine on antibody synthesis in vitro and in vivo. (1983) (11)
Pulmonary localization of intravenously injected liposomes. (1980) (10)
The cell surface and cancer metastasis. (1986) (10)
A truncated v-abl-derived tyrosine-specific tyrosine kinase expressed in Escherichia coli. (1989) (10)
Heterogeneity in the surface properties of B16 melanoma cells from sublines with differing metastatic potential detected via two-polymer aqueous-phase partition. (1986) (10)
A new cytochemical method for ultrastructural detection of liposomes in tissues in vivo. (1989) (9)
Cellular and Molecular Aspects of Inflammation (1988) (9)
Novel panomic validation of time to next treatment (TNT) as an effective surrogate outcome measure in 4,729 patients. (2016) (9)
Reconstitution of the Gs protein from B16 melanoma clones of high and low experimental metastatic potential into S49 cyc-membranes. (1987) (9)
Chemosensitization of murine fibrosarcoma cells to drugs affected by the multidrug resistance phenotype by the antidepressant trazodone - an experimental-model for the reversal of intrinsic drug-resistance. (1992) (9)
Cell surface changes in virus-induced cell fusion. 2. Changes in cell coat thickness. (1971) (9)
Lectin-mediated agglutination of murine lymphoma cells. Cell surface deformability and reversibility of agglutination by saccharides. (1979) (9)
Differential effects of intact subunits and nicked fragments of concanavalin A on immune functions in vitro and in vivo. (1983) (9)
Inhibition of antibody synthesis by histamine in concanavalin A-treated mice: the possible role of glucocorticosteroids. (1982) (8)
Effect of plasma membrane lipid composition on cellular susceptibility to virus-induced cell fusion. (1972) (8)
Recruitment of exogenous macrophages into metastases at different stages of tumor growth (1987) (8)
A high performance liquid chromatography assay for the rapid analysis of the subunit content of concanavalin A. (1982) (8)
Mixed-culture polykaryocytosis: a new form of cellular recognition behaviour. (1970) (8)
Targeting of drugs : anatomical and physiological considerations (1988) (8)
The Cellular Interactions of Metastatic Tumor Cells with Special Reference to Endothelial Cells and their Basal Lamina-Like Matrix (1984) (8)
Clonal analysis of the malignant properties of B16 melanoma cells treated with the DNA hypomethylating agent 5-azacytidine (1988) (7)
Binding of histamine and histamine analogs to lymphocyte subsets analyzed by flow cytometry. (1985) (7)
Tumorigenic and metastatic properties of " normal " and ras-transfected NIH / 3 T 3 cells ( malignancy / organ colonization ) (7)
Surface molecules and tumour-cell metastatic properties. (1980) (7)
Inhibition of macrophage activation and tumor cell cytolysis by cyclosporin-A. (1984) (7)
Enhancement of virus-induced cell fusion by phytohemagglutinin. (1976) (7)
New Frontiers in the Study of Gene Functions (1987) (6)
Valuing Health Care: Improving Productivity and Quality (2012) (6)
Virus-receptor interactions. (1982) (6)
The role of lysosomes in virus-induced cell fusion. 1. Cytochemical studies. (1971) (6)
Privacy and confidentiality in the age of genetic engineering. (1999) (6)
CHAPTER 5 – TUMOR CELL HETEROGENEITY AND THE PATHOGENESIS OF CANCER METASTASIS (1985) (6)
Enucleation of cultured animal cells by cytochalasin B. (1978) (6)
Regulatory and Reimbursement Innovation (2013) (6)
Virus infection and the cell surface (2005) (6)
Activation of tumoricidal properties in murine macrophages by intravenous injection of muramyl dipeptide encapsulated within liposomes as a treatment for spontaneous metastasis. (1981) (5)
The role of lysosomes in virus-induced cell fusion. 2. Modification of the cell surface. (1971) (5)
In vitro systems for studying the interaction of metastatic tumor cells with endothelial cells and subendothelial basement membranes (1984) (5)
Alterations in lipid-linked oligosaccharide metabolism in human melanoma cells concomitant with induction of stress proteins. (1987) (5)
Serving Individuals and Populations Within Integrated Health Systems: A Bridge Too Far? (2019) (5)
New insights into receptor regulation. (1984) (5)
Biological membranes and malignancy: an overview of pharmacological opportunities. (1986) (5)
Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabine+placebo versus gemcitabine+evofosfamide and identifies candidate targets. (2018) (5)
Stimulation of Host Response Against Metastatic Tumors by Liposome-Encapsulated Immunomodulators (1982) (4)
Policy forum: health care delivery. Building populations genetics resources using the U.K. NHS. (1999) (4)
[15] Liposome-mediated macrophage activities (1987) (4)
Induction of suppressor cells, interleukin-2 production and mitogenesis with monomeric concanavalin A: different actions of tetrameric and monomeric concanavalin A. (1985) (4)
Targeting of drugs 3 : the challenge of peptides and proteins (1992) (4)
Cell fusion by Newcastle disease virus in the absence of RNA synthesis. (1971) (4)
Liposome-encapsulated macrophage activation agents and active non-specific immunotherapy of neoplastic disease. (1982) (4)
Life-sciences R&D, national prosperity, and industrial competitiveness. (1997) (4)
The challenge of liposome targeting in vivo (2018) (3)
Perspective from the founding editors. Preface. (2013) (3)
Patents, ethics and improving healthcare. (1997) (3)
Mechanism of envelopment of herpesvirus by the nucelar envelope. (1973) (3)
The influence of cell surface properties on the arrest of circulating melanoma cells. (1980) (3)
Isolation and immunological characterization of the mammalian 32-/34-kDa stress protein. (1988) (3)
Synthesis and evaluation of multisubstrate inhibitors of an oncogene-encoded tyrosine-specific protein kinase. 1. (1988) (3)
Targeting of drugs 2 : optimization strategies (1990) (3)
Interaction of concanavalin A with the surface of virus-infected cells. (1975) (3)
Electron microscope study of the morphogenesis of a new canine herpesvirus in dog kidney cells (2005) (3)
The globalization of US medical countermeasure production and its implications for national security. (2012) (3)
Protecting the Homeland, Report of the Defense Science Board, 2000 Summer Study Executive Summary. Volume 1 (2001) (3)
Alterations in the phosphoprotein composition of tumor cell clones induced by cell culture techniques used routinely in assessing metastatic behavior in vivo (1985) (3)
Augmentation of human natural killer cell activity by influenza virus antigens produced in Escherichia coli. (1987) (3)
International control measures: the Biological Weapons Convention and its projected Protocol. (2000) (2)
Drug-containing lipid vesicles render drug-resistant cell sensitive to actinomycin D. (1976) (2)
Do not sell regulatory science short (2021) (2)
A vision for spaceflight microbiology to enable human health and habitat sustainability (2021) (2)
Facing reality in preparing for biological warfare: a conversation with George Poste. Interview by Jeff Goldsmith. (2002) (2)
Characterization of a new canine herpes virus (2005) (2)
Poly-ligand profiling (PLP) to differentiate pancreatic cancer patients who benefit from gemcitabine+evofosfamide versus gemcitabine+placebo treatment. (2018) (2)
Liposome-Mediated Drug Delivery to Mononuclear Phagocytes In Vivo: Applications in Antimicrobial Therapy (1986) (2)
Current concepts of cancer metastasis. (1985) (2)
Hype, Hope and Honesty (1984) (1)
Re-classification of NSAIDs. (1997) (1)
Breaking down silos for improved biomarker development: an interview with George Poste (2015) (1)
New wave cancer therapy: Disease-specific strategies (1988) (1)
1 – Colorectal Carcinoma: Key Issues (1990) (1)
Erratum: Uncensored exchange of scientific results (Proceedings of the National Academy of Sciences (2003) 100, 4, (1464) DOI: 10.1073/pnas.0630491100) (2012) (1)
The Pharmaceutical Industry and Health Care (1985) (1)
The prospects for a human malaria vaccine (1988) (1)
Use of panomic assessment to reveal DNA repair alterations and to predict potential therapeutic response to taxane-platinum combination therapy in prostate cancer. (2016) (1)
Obstacles to the Development of Novel Thrombolytic Agents for Acute Myocardial Infarction Therapy: Is the Good the Enemy of the Best? (1994) (1)
Pharmaceutical applications: Editorial overview (1991) (1)
Novel agents in the treatment of atherosclerosis (1994) (1)
Experimental Models for Studying the Pathogenesis and Therapy of Metastatic Disease (1986) (1)
Editors farewell (2004) (1)
Electron microscopic study of nuclear and nucleolar changes in cells infected with canine distemper virus (CDV) (2005) (1)
Glycoprotein synthesis by human colon carcinoma cells in vitro and as xenografts in nude mice (1987) (0)
Adaptive dynamic artificial poly-ligand targeting (ADAPT) of the plasma exosome proteome: A highly multiplexed non-invasive diagnostic discovery platform. (2016) (0)
Growth regulation in colon carcinoma (1987) (0)
Molecular Medicine, Population Genetics and the Future of Healthcare Delivery (2000) (0)
Liposome-mediated macrophage activities. (1987) (0)
Diagnostic methods using exosomes (2009) (0)
Liposomes and targeted drug delivery to macrophages: A potential system for improved therapy of microbial infections* (1984) (0)
The influence of the primary tumor on the development of pulmonary metastases. Asbtr. (1983) (0)
The role of calcium in macrophage-mediated tumor cell cytotoxicity. Abstr. (1983) (0)
Cell biology monographs. Vol. 3. Lysosomes: A survey: by. E. Holtzman, Springer-Verlag, Wien and New York, 1976. DM130.- ($8.98) (xi+298 pages) (1977) (0)
Cell Surface Alterations and the Metastatic Behavior of Tumor Cells (1986) (0)
Targeting of Drugs 3 (1992) (0)
Abstract P2-09-09: Polyligand profiling differentiates cancer patients according to their benefit of treatment (2018) (0)
Cell cycle regulation (1997) (0)
Cancer Immunology Cancer Biology Reviews, Vol. 1 John J. Marchalonis Michael G. Hanna Isaiah J. Fidler (1981) (0)
Cell-Surface Research (1981) (0)
Effects of local anesthetics on cytoskeletal trans membrane control of cell surface receptors (1976) (0)
RE-CLASSIFICATION OF NSAIDS. AUTHOR'S REPLY (1997) (0)
Inhibition of phytohemagglutinin (PHA) induced proliferation of human peripheral blood lymphocytes (HPBL) by histamine (1982) (0)
Re-classification of NSAIDs (multiple letters) [2] (1997) (0)
Book ReviewMembrane Molecular Biology of Neoplastic Cells. (1976) (0)
Biological Membranes and Malignancy: (1986) (0)
Abstract LB-135: Adaptive dynamic artificial poly-ligand targeting (ADAPT) enables plasma-based exosome profiling with potential diagnostic utility (2016) (0)
Stimulation of host resistance to metastatic tumors by macrophage activating agents encapsulated in liposomes. (1983) (0)
Whatever happed to the industry I was told to distrust? (1983) (0)
Targeting of Drugs 4 (1994) (0)
Membrane-Membrane Interactions. Norton B. Gilula (1981) (0)
Biotechnology and the evolution of molecular medicine (2001) (0)
Of individual lung metastases. (1982) (0)
Macrophage activation in vivo: New approaches to the therapy of metastatic tumors (1984) (0)
Cyclic amp metabolism of b16 melanoma cell clones. Abstr. (1983) (0)
Isaiah J. (Josh) Fidler, DVM, PhD, FAACR: In Memoriam (1936–2020)—A Visionary Research Career Dedicated to Understanding the Complexities of Cancer Metastasis (2020) (0)
A monoclonal antibody that recognizes an antigen expressed on tumoricidal macrophages. Abstr. (1983) (0)
Dopamine receptor agonists (1984) (0)
miRNA expression in the characterisation and classification of cancer (2009) (0)
New HistochemicalMethod for Measuring IntratumoralMacrophagesand Macrophage Recruitmentinto ExperimentalMÃ©tastases (1983) (0)
Hagan et al. reply (1997) (0)
Enzymatic properties of an Abelson murine leukemia virus-encoded tyrosine-specific kinase produced in E. coli (1985) (0)
Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes (2018) (0)
Cellular programmes for growth, differentiation and neoplasia Helsinki, Finland 19–23 July 1992 (1992) (0)
Liposome mediated delivery of biological response modifiers (BRM) to macrophages in vivo: A new strategy for therapy of neoplastic disease (1985) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With George Poste?

George Poste is affiliated with the following schools:

George Poste's Academic­Influence.com Rankings

Why Is George Poste Influential?

George Poste's Published Works

Published Works

Other Resources About George Poste

What Schools Are Affiliated With George Poste?

George Poste's AcademicInfluence.com Rankings